Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Effects of Hydromorphone on Responses to Verbal Tasks (HESS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02205983
Recruitment Status : Completed
First Posted : August 1, 2014
Results First Posted : October 9, 2018
Last Update Posted : October 9, 2018
Sponsor:
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
University of Chicago

Brief Summary:
In this study, the investigators will examine the effects of hydromorphone, as compared to placebo, upon physiological, subjective, and hormonal responses to a stressful speech task and a non-stressful control task in healthy adults. There is strong evidence in support of the role of endogenous opioids and opiates in mediating social behavior in humans and other animals, and particularly, in social distress. The investigators have recently shown that buprenorphine, a partial mu-opioid agonist, reduces cortisol responses to stress. Here, the investigators propose to further explore the role of the opioid system in mediating stress responses in humans through the use of hydromorphone, a full mu opioid agonist, in addition to acetaminophen. The investigators hypothesize that like acetaminophen, hydromorphone will reduce both physiological and subjective measures of stress.

Condition or disease Intervention/treatment Phase
Healthy Drug: 2 mg hydromorphone Drug: 1000 mg Acetaminophen Drug: 4 mg hydromorphone Drug: dextrose Not Applicable

Detailed Description:
Participants be randomly assigned to receive 1000 mg acetaminophen, 2mg hydromorphone, 4mg hydromorphone, or placebo at each of two sessions; one during which they well participate in a stressful speaking task, and one during which they'll participate in a nonstressful control task. Physiological and subjective measures will be taken throughout each session.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 50 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: The Effects of Hydromorphone on Responses to Verbal Tasks
Actual Study Start Date : January 2015
Actual Primary Completion Date : July 2016
Actual Study Completion Date : September 2016

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: 2 mg hydromophone
Healthy adult volunteers will receive 2 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion.
Drug: 2 mg hydromorphone
We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.

Experimental: 4 mg hydromphone
Healthy adult volunteers will receive 4 mg hydromophone. Hydromorphone is a mu-opioid agonist used clinically for pain management. Plasma concentrations of hydromorphone peak approximately 60 min after ingestion
Drug: 4 mg hydromorphone
We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.

Experimental: 1000 mg acetaminophen
Healthy adult volunteers will receive 1000 mg acetaminophen. Acetaminophen is a COX inhibitor that is used clinically as an analgesic and antipyretic. The dose administered here has been shown to reduce neural and subjective responses to social rejection, and it also peaks about 60 min after ingestion.
Drug: 1000 mg Acetaminophen
We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.

Placebo Comparator: Dextrose
Healthy adult volunteers will recieve Dextrose (placebo).
Drug: dextrose
We are administering dextrose to healthy volunteers for our placebo group.




Primary Outcome Measures :
  1. Subjective Effects as Assessed by Score on "Feel Drug", "Feel High", "Like Drug", and "Want More" Subscales of the Drug Effects Questionnaire [ Time Frame: End of study (time 0 and approximately 4 weeks later), week 4 reported. ]
    The Drug Effects Questionnaire (DEQ) is a visual analog scale questionnaire that assesses the extent to which subjects experience four subjective states: "Feel Drug", "Feel High", "Like Drug", and "Want More". The "Feel Drug", "Feel High", "Like Drug", and "Want More" subscales are reported. All subscales are scored on a visual analogue scale (scroll bar on computer screen) ranging from 0-100. 100 represents the highest score for that subjective state, and the higher the score, the worse the outcome. The values shown below are only from week 4



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult volunteers

Exclusion Criteria:

  1. any current medical condition requiring medication or abnormal electrocardiogram
  2. current or past medical condition considered to be a contraindication for the study conditions
  3. any current Axis I psychiatric disorder (APA, 1994) including Substance Use Disorder, or Anxiety Disorder or Major Depression in the past year, any history of psychosis
  4. less than high school education
  5. lack of fluency in English
  6. night shift work
  7. Pregnancy, lactation or plans to become pregnant.
  8. Use of hormonal contraception.
  9. Daily cigarette smokers i.e., >7 cigarettes per week

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02205983


Locations
Layout table for location information
United States, Illinois
University of Chicago Hospital
Chicago, Illinois, United States, 60637
Sponsors and Collaborators
University of Chicago
National Institute on Drug Abuse (NIDA)
Investigators
Layout table for investigator information
Principal Investigator: Harriet de Wit, PhD University of Chicago
Study Chair: Jerome Jaffe, MD University of Maryland
Layout table for additonal information
Responsible Party: University of Chicago
ClinicalTrials.gov Identifier: NCT02205983    
Other Study ID Numbers: UC13-1027
R01DA002812 ( U.S. NIH Grant/Contract )
First Posted: August 1, 2014    Key Record Dates
Results First Posted: October 9, 2018
Last Update Posted: October 9, 2018
Last Verified: September 2018
Keywords provided by University of Chicago:
enrolling
adult
volunteers
Additional relevant MeSH terms:
Layout table for MeSH terms
Acetaminophen
Hydromorphone
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Antipyretics
Analgesics, Opioid
Narcotics
Central Nervous System Depressants